Monotherapy versus Dual Therapy for Community-Acquired Pneumonia in Hospitalized Patients

Martinez, Fernando J.
May 2004
Clinical Infectious Diseases;5/15/2004 Supplement, Vol. 38, pS328
Academic Journal
Several medical-specialty professional societies have suggested that combination therapy with a β-lactam plus a macrolide or doxycycline or monotherapy with a "respiratory quinolone" (i.e., levofloxacin, gatifloxacin, moxifloxacin, or gemifloxacin) are optimal first-line therapy for patients hospitalized with community-acquired pneumonia. These recommendations are based predominantly on retrospective studies that suggest improved rates of morbidity and mortality and hospital length of stay among patients treated in such a fashion. Well- designed, prospective, randomized studies confirming this tenet of therapy have not been published, although numerous prospective studies have provided indirect confirmation. The biological rationale for such a differential response (i.e., favoring combination therapy or fluoroquinolone therapy) includes the immunomodulatory effects of macrolides or more-optimal treatment of primary infection or coinfection with atypical pathogens. Well-designed, prospective, randomized trials are required to best define the effectiveness of combination therapy with a β-lactam plus macrolide or doxycycline or with a respiratory quinolone in hospitalized patients with community-acquired pneumonia.


Related Articles

  • 36-Year-Old Man With Productive Cough and Diffuse Rash. Kumar, Gautam; Fadel, Hind J.; Beckman, Thomas J. // Mayo Clinic Proceedings;Jul2006, Vol. 81 Issue 7, p945 

    The article examines the case of a 36-year old farmer presented for evaluation of cough with white sputum, pleuritic chest pain and chills with rigors. The patient may be treated with an advanced-generation macrolide due to negative signs of risk factors. He was diagnosed to have Stevens-Johnson...

  • Community-acquired pneumonia: Atypical may not be unusual. Pinkowish, Mary Desmond // Patient Care;1/30/2000, Vol. 34 Issue 2, p15 

    Reports on results of a study of associations between initial antimicrobial regimens and mortality among patients with community-acquired pneumonia (CAP). Hypothesis on the effectiveness of regimens that include agents active against atypical pathogens; Probability of decreased mortality with...

  • MACROLIDES IN COMMUNITY-ACQUIRED PNEUMONIA. Parks, Douglas S.; Johnson, Kenneth H. // Journal of Family Practice;Aug1998, Vol. 47 Issue 2, p95 

    The article reports on a study regarding the significance of adding a macrolide-based antibiotic in treating hospitalized immunocompetent patients with community-acquired pneumonia (CAP). Several large prospective studies have identified atypical pathogens in 10% to 25% of CAP, prompting the...

  • Macrolide-Resistant Streptococcus pneumoniae in Community-Acquired Pneumonia: Clinical and Microbiological Outcomes for Patients Treated with Levofloxacin. Kahn, J .B.; Wiesinger, B. A.; Xiang, J. // Clinical Infectious Diseases;1/15/2004 Supplement 1, Vol. 38, pS24 

    The rapid emergence and increasing prevalence of antimicrobial resistance in Streptococcus pneumoniae have greatly complicated the choice of empirical treatment for community-acquired pneumonia (CAP). The newer macrolides, azithromycin and clarithromycin, have been popular choices for empirical...

  • Atypical pneumonia in adults in southern Africa. Dlamini, S. K.; Mendelson, M. // South African Family Practice;Aug/Sep2012, Vol. 54 Issue 4, p286 

    The true incidence of Legionella pneumophilia, Mycoplasma pneumoniae, Chlamydophila pneumoniae and Coxiella burnetti, the so-called atypical pathogens that cause adult community-acquired pneumonia in southern Africa, is unknown. Although there are a lack of community-based studies,...

  • The Impact of Steroids Given with Macrolide Therapy on Experimental Mycoplasma pneumoniae Respiratory Infection. Tagliabue, C.; Salvatore, C. M.; Techasaensiri, C.; Mejias, A.; Torres, J. P.; Katz, K.; Gomez, A. M.; Esposito, S.; Principi, N.; Hardy, R. D. // Journal of Infectious Diseases;10/15/2008, Vol. 198 Issue 8, p1180 

    Background. Systemic steroids have been advocated in addition to antimicrobial therapy for severe Mycoplasma pneumoniae pneumonia. We evaluated the efficacy of clarithromycin, dexamethasone, and combination therapy for M. pneumoniae respiratory infection. Methods. Mice infected with M....

  • Gastric acid suppressant use linked to pneumonia. Polak, Monika // GP: General Practitioner;11/5/2004, p9 

    The article presents information on gastric acid suppressant use linked to pneumonia. Taking gastric acid suppressants can increase risk of community acquired pneumonia (CAP), according to a Dutch study. It showed CAP risk almost doubled among current users of proton pump inhibitors (PPIs)...

  • Review: empirical atypical coverage does not reduce mortality in hospitalised patients with community acquired pneumonia. Shefet, D. // Evidence Based Medicine;Jun2006, Vol. 11 Issue 3, p74 

    The article presents a study that examines whether empirical antibiotic coverage of atypical pathogens would reduce mortality and would improve clinical efficacy in hospitalized patients with community acquired pneumonia. Results in this study show that treatment groups did not differ in...

  • Azithromycin Extended Release: A Review of its Use in the Treatment of Acute Bacterial Sinusitis and Community-Acquired Pneumonia in the US. Swainston, Tracy; Kean, Susan J. // Drugs;2007, Vol. 67 Issue 5, p773 

    Azithromycin is a macrolide antibacterial agent. The novel microspheres oral extended-release formulation (Zmaxâ„¢) is the first antibacterial drug approved in the US for administration as a single dose in adult patients with mild to moderate acute bacterial sinusitis (ABS) or...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics